This article was originally published in The Gray Sheet
Executive SummaryAcquisition of development stage CardioGene Therapeutics gives the Natick, Massachusetts firm a foothold in the gene therapy market for cardiovascular diseases such as angiogenesis, restenosis and congestive heart failure. Boston Scientific the purchases all outstanding stock in the Princeton, New Jersey firm, which holds patent positions covering the "use of device technology for delivery of genetic material to sites within the vasculature and the myocardium"
You may also be interested in...
Discussions on the shape of health care have moved from “reimagining” to the next stage: building and executing on the vision. That is the thrust of EY’s NextWave Report: New Horizons 2019. Additionally, for medtechs seeking business continuum, “duality” is now a preoccupying thought.
The idea that public corporations have obligations that extend beyond the fiduciary responsibility to shareholders will be the dominant measure of responsible business behavior in the coming decade. Uncertainty about the extent of these commitments – commonly referenced as the environmental, social and governance (ESG) agenda – has produced equally variable responses from companies in the health care business.